Literature DB >> 18769777

[Guidelines for chagas disease: Part IV. Chagas disease in immune compromised patients].

Werner Apt B1, Ingrid Heitmann G, M Isabel Jercic L, Leonor Jotré M, Patricia Muñoz C Del V, Isabel Noemí H, Ana M San Martin V, Jorge Sapunar P, Marisa Torres H, Inés Zulantay A.   

Abstract

A summary of different kind of immune suppressed hosts and the importance of Trypanosoma cruzi infection in this group of patients is presented. Then, most relevant aspects of immune compromised host-parasite interaction are analyzed such as the moment of acquiring the infection, immune compromise level, mechanisms of acquisition the infection and geographic region. Clinical features of primary infection and reactivation of infection in chronic Chagasic patients are described making special emphasis in solid organ transplant and BMT. Chagas disease in AIDS patients is discussed including its treatment, follow up, monitoring the immune compromise level and prophylaxis.

Entities:  

Mesh:

Year:  2008        PMID: 18769777     DOI: /S0716-10182008000400008

Source DB:  PubMed          Journal:  Rev Chilena Infectol        ISSN: 0716-1018            Impact factor:   0.520


  2 in total

1.  New Amino Naphthoquinone Derivatives as Anti-Trypanosoma cruzi Agents Targeting Trypanothione Reductase.

Authors:  Christian Espinosa-Bustos; Mariana Ortiz Pérez; Alonzo Gonzalez-Gonzalez; Ana María Zarate; Gildardo Rivera; Javier A Belmont-Díaz; Emma Saavedra; Mauricio A Cuellar; Karina Vázquez; Cristian O Salas
Journal:  Pharmaceutics       Date:  2022-05-25       Impact factor: 6.525

2.  Chagas disease reactivation: cutaneous manifestations in a transplanted patient.

Authors:  Maria Guillermina Ferraresso; Ana Clara Torre; Maria Manuela Martínez Piva; Laura Barcan
Journal:  An Bras Dermatol       Date:  2018 Nov/Dec       Impact factor: 1.896

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.